Question 1

What are the potential side effects of TUB-040?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC clinical trial (NCT06303505). Contact the study team or your healthcare provider for specific answers.

Question 2

How does this trial compare to other treatment options I have?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC clinical trial (NCT06303505). Contact the study team or your healthcare provider for specific answers.

Question 3

What will the treatment schedule look like, and how often will I need to come in for visits?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC clinical trial (NCT06303505). Contact the study team or your healthcare provider for specific answers.

Question 4

What tests will I need to undergo during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC clinical trial (NCT06303505). Contact the study team or your healthcare provider for specific answers.

Question 5

How will my progress be monitored throughout the study?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC clinical trial (NCT06303505). Contact the study team or your healthcare provider for specific answers.

Question 6

What happens if I experience side effects or my cancer worsens during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC clinical trial (NCT06303505). Contact the study team or your healthcare provider for specific answers.

What this study is about